Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

An estimated 4,500 prescriptions have been filled in 2024 so far, Iwatsubo said. About 80 percent of patients have mild cognitive impairment, the rest have mild dementia. Most are in their 70s, and ...

Most discontinued anti-tau antibodies (red) targeted tau’s N-terminus. Of the antibodies currently in trials (green), bepranemab and E2814 presented results at CTAD, while JJ-63733657/posdinemab and ...

Seeking ways to improve the safety of anti-amyloid antibodies, John Sims of Eli Lilly & Company presented a simple option to do so for donanemab at this year’s Clinical Trials on Alzheimer’s Disease ...

In recent years, CryoEM has enabled scientists to decipher the structures of the fibrils that form various deposits in neurodegenerative disease. They have not only solved disease-specific folding ...

“Bruce had a brilliant career in both academia and industry and left an indelible mark on the Alzheimer’s disease drug development landscape,” noted Robert Vassar, Northwestern University, Chicago ...

Tg12099 rats overexpress the 0N4R isoform of human tau with the P301S mutation linked to frontotemporal dementia. The MAPT transgene is driven by the rat Prnp promoter. Overexpress the 0N4R isoform of ...

These tau knockout rats were created through transcription activator-like effector nuclease (TALEN)-mediated targeting of exon 2 of the rat Mapt gene (Ayers, Lopez et al., 2024). Tau protein was ...